Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-25-057069
Filing Date
2025-06-06
Accepted
2025-06-06 08:10:07
Documents
2
Period of Report
2025-06-05

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm2517151-1_3seq1.html 3  
1 OWNERSHIP DOCUMENT tm2517151-1_3seq1.xml 3 1612
2 EXHIBIT 24 tm2517151d1_ex24.htm EX-24 5111
  Complete submission text file 0001104659-25-057069.txt   8365
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Issuer) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address 3 RABBIT RUN DRIVE NEW HOPE PA 18938
Business Address
Torres Denice (Reporting) CIK: 0001820278 (see all company filings)

Type: 3 | Act: 34 | File No.: 000-15006 | Film No.: 251028933